Literature DB >> 19525150

Determination of prevalence of depression in an epilepsy clinic using a brief DSM-IV-based self-report questionnaire.

Nicole A Seminario1, Sarah Tomaszewski Farias, Julie Jorgensen, James A Bourgeois, Masud Seyal.   

Abstract

Depression in epilepsy is common, underrecognized, and an indicator of quality of life. The Patient Health Questionnaire nine-item depression scale (PHQ-9) is a self-administered questionnaire based on Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) criteria with high sensitivity and specificity for diagnosing depression. Using the PHQ-9, we determined that one-third of 263 patients seen in an epilepsy clinic had scores consistent with major depression. Seizure-free patients had lower depression scores than those with persistent seizures. Depression scores were not related to the number or type of antiepileptic drugs used. One-half of patients with scores consistent with major depression were not on antidepressant medication. The brevity of the PHQ-9 is conducive to routine screening of patients with epilepsy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525150     DOI: 10.1016/j.yebeh.2009.05.007

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  11 in total

Review 1.  Depression in epilepsy: a critical review from a clinical perspective.

Authors:  Christian Hoppe; Christian E Elger
Journal:  Nat Rev Neurol       Date:  2011-07-12       Impact factor: 42.937

2.  Validation of the Patient Health Questionnaire-9 (PHQ-9) for depression screening in adults with epilepsy.

Authors:  Jaivir S Rathore; Lara E Jehi; Youran Fan; Sima I Patel; Nancy Foldvary-Schaefer; Maya J Ramirez; Robyn M Busch; Nancy A Obuchowski; George E Tesar
Journal:  Epilepsy Behav       Date:  2014-07-26       Impact factor: 2.937

3.  Evaluation of depression risk in LGI1 mutation carriers.

Authors:  Gary A Heiman; Kay Kamberakis; Richard Gill; Sergey Kalachikov; Timothy A Pedley; W Allen Hauser; Ruth Ottman
Journal:  Epilepsia       Date:  2010-07-26       Impact factor: 5.864

4.  Depressive Symptom Severity in Individuals With Epilepsy and Recent Health Complications.

Authors:  Neha Kumar; Rigzin Lhatoo; Hongyan Liu; Kari Colon-Zimmermann; Curtis Tatsuoka; Peijun Chen; Mustafa Kahriman; Martha Sajatovic
Journal:  J Nerv Ment Dis       Date:  2019-04       Impact factor: 2.254

5.  Phyllathin From Phyllanthus Amarus Ameliorates Epileptic Convulsion and Kindling Associated Post-Ictal Depression in Mice via Inhibition of NF-κB/TLR-4 Pathway.

Authors:  Zhang Tao; Hu Chun-Yan; Peng Hua; Yang Bin-Bin; Tang Xiaoping
Journal:  Dose Response       Date:  2020-08-03       Impact factor: 2.658

6.  Alexithymia and posttraumatic stress disorder following epileptic seizure.

Authors:  Man Cheung Chung; Rachel D Allen
Journal:  Psychiatr Q       Date:  2013-09

7.  Demographic and Clinical Correlates of Seizure Frequency: Findings from the Managing Epilepsy Well Network Database.

Authors:  Erdong Chen; Martha Sajatovic; Hongyan Liu; Ashley Bukach; Curtis Tatsuoka; Elisabeth Welter; Samantha S Schmidt; Yvan A Bamps; Shelley C Stoll; Tanya M Spruill; Daniel Friedman; Charles E Begley; Ross Shegog; Robert T Fraser; Erica K Johnson; Barbara C Jobst
Journal:  J Clin Neurol       Date:  2018-02-28       Impact factor: 3.077

8.  Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy.

Authors:  Rowena M A Packer; Luisa De Risio; Holger A Volk
Journal:  BMC Vet Res       Date:  2017-04-07       Impact factor: 2.741

9.  Depression in patients with epilepsy: a study from enugu, South East Nigeria.

Authors:  Io Onwuekwe; Os Ekenze; Ju Ejekwu
Journal:  Ann Med Health Sci Res       Date:  2012-01

10.  Depressogenic medications and other risk factors for depression among Polish patients with epilepsy.

Authors:  Magdalena Bosak; Wojciech Turaj; Dominika Dudek; Marcin Siwek; Andrzej Szczudlik
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-30       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.